Clearside

Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference

Retrieved on: 
Mittwoch, Mai 8, 2024
Citizenship, Clearside, Conference, Webcast, Fireside, Eye, Pharming, MBA

ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 9:30 a.m.

Key Points: 
  • ALPHARETTA, Ga., May 08, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 9:30 a.m.
  • ET in New York, NY.
  • A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations .
  • An archive of the webcast will be available for three months.

Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Dienstag, April 2, 2024
Clearside, Webcast, MBA, Eye, Fireside, Pharming, Conference

ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 3:00 p.m.

Key Points: 
  • ALPHARETTA, Ga., April 02, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, and Victor Chong, M.D., MBA, Chief Medical Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 3:00 p.m.
  • ET.
  • A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations .
  • An archive of the webcast will be available for three months.

Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024

Retrieved on: 
Donnerstag, Februar 29, 2024
Eye, Clearside, Webcast

Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Key Points: 
  • Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
  • The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations .
  • The live call can be accessed by dialing 888-506-0062 (U.S.) or 973-528-0011 (international) and entering conference code: 694916.
  • The Company suggests participants join 15 minutes in advance of the event.

Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering

Retrieved on: 
Mittwoch, Februar 7, 2024
Security (finance), Montgomery Street, Clearside, Exercise, Attention, Investment, Sale, Eye, Form

The offer price for one share of common stock and accompanying warrant to purchase one share of common stock will be $1.35.

Key Points: 
  • The offer price for one share of common stock and accompanying warrant to purchase one share of common stock will be $1.35.
  • The offering is expected to close on or about February 9, 2024, subject to the satisfaction of customary closing conditions.
  • The gross proceeds to Clearside from this offering are expected to be approximately $15.0 million, before deducting the placement agent’s fees and other offering expenses payable by Clearside.
  • Clearside intends to use the net proceeds from this offering for working capital and general corporate purposes.

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Montag, November 13, 2023
Potential, Visual acuity, Patient, Research, American Medical Association, Targeted drug delivery, Conference, American Academy of Ophthalmology, R, Diabetes, Diabetic retinopathy, Webcast, Literature, American Academy, Administration, DME, G&A, Research and development, Physician, Paratriathlon, Retina, Drug delivery, Pharming, Eye, Intravitreal injection, BioCryst Pharmaceuticals, SCS, Edema, AAO, Melanoma, AURA, Solubility, Partnership, AMD, Clearside, Bausch & Lomb, OASIS, Axitinib, Plasma, Clinical trial, CLS, CPT, Conference call, UME, Injection, HIV disease progression rates, Pharmaceutical industry, Nursing, Video game

ALPHARETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Key Points: 
  • ET -
    ALPHARETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
  • Other Income: Other income for the third quarter of 2023 was $0.4 million, compared to $0.2 million for the third quarter of 2022.
  • Other Expense: Non-cash interest expense for the third quarter of 2023 was $2.6 million, compared to $1.3 million in the third quarter of 2022.
  • Clearside’s management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference

Retrieved on: 
Mittwoch, November 8, 2023
Clearside, Pharming, Eye, Conference, Webcast, Pharmaceutical industry, Broadcasting, Private investigator

ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023 at 8:35 a.m.

Key Points: 
  • ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023 at 8:35 a.m.
  • ET in New York, NY.
  • A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations .
  • An archive of the webcast will be available for three months.

Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual Meeting

Retrieved on: 
Dienstag, November 7, 2023
TKI, Neoplasm, Patient, SCS, FDA, Cohort, Axitinib, I Am the Moon, AMD, AAO, Safety, Inflammation, Melanoma, Diabetic retinopathy, HIV disease progression rates, Pharming, OASIS, American Academy, Retina, Paratriathlon, Annual general meeting, Clearside, Eye, Suprachoroidal drug delivery, Visual acuity, Oxygen toxicity, Pharmaceutical industry

“The AAO meeting held over the past week was exceptionally positive for Clearside and our clinical development partners,” said, George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer.

Key Points: 
  • “The AAO meeting held over the past week was exceptionally positive for Clearside and our clinical development partners,” said, George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer.
  • Two of our partners, REGENXBIO and Aura Biosciences, presented new, positive Phase 2 safety and clinical efficacy data from their respective programs utilizing our SCS Microinjector.
  • The findings from the survey indicated that physicians found the XIPERE injection easy to learn, with patient outcomes consistent with clinical trial data.
  • Clearside’s medical meeting presentations can be accessed on the Company’s Publications and Presentations page.

BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®

Retrieved on: 
Freitag, November 3, 2023
BioCryst Pharmaceuticals, SCS, Research, Research and development, Plasma, RESEARCH, DME, Diabetes, Hereditary angioedema, Edema, R, HAE, Pharming, Diabetic retinopathy, Nature and Wildlife Discovery Center, Paratriathlon, Eye, PARK, Patient, Solubility, Pharmaceutical industry, Clearside

ALPHARETTA, Ga. and RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Clearside Biomedical, Inc. (Nasdaq: CLSD) today announced the entry into a license agreement enabling BioCryst to develop its investigational plasma kallikrein inhibitor, avoralstat, with Clearside’s SCS Microinjector® to deliver avoralstat directly to the back of the eye through the suprachoroidal space to treat patients with diabetic macular edema (DME).

Key Points: 
  • “Many DME patients are not effectively controlled with anti-VEGF therapy, so it is exciting to target plasma kallikrein by combining avoralstat with delivery into the suprachoroidal space using Clearside’s proprietary SCS Microinjector.
  • Avoralstat has high potency and low solubility, which are two characteristics important to achieving potential efficacy with reduced dosing frequency in the eye for DME patients.
  • Avoralstat was previously evaluated in an oral formulation in a Phase 3 clinical trial in patients with hereditary angioedema (HAE).
  • “Treating patients with DME by delivering avoralstat directly to the suprachoroidal space using the SCS Microinjector expands the reach of our proprietary SCS injection platform to a greater number of patients.

Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting

Retrieved on: 
Donnerstag, November 2, 2023
Patient, Physician, AAO, Safety, Triamcinolone, OASIS, Melanoma, Surgeon, American Academy, American Academy of Ophthalmology, Annual general meeting, Clearside, Eye, Suprachoroidal drug delivery, Pharmaceutical industry

ALPHARETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple oral and poster presentations will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting taking place November 3 – 6, 2023 in San Francisco, CA.

Key Points: 
  • ALPHARETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple oral and poster presentations will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting taking place November 3 – 6, 2023 in San Francisco, CA.
  • AAO is the world's largest association of eye physicians and surgeons.
  • Presentations will be delivered by leading physicians on behalf of Clearside and the Company’s commercial and development partners:
    Title: Safety and Tolerability of Suprachoroidal CLS-AX (Axitinib Injectable Suspension) in nAMD Patients in a Phase 1/2A Study, OASIS
    Title: Experience With Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Physician Survey
    Title: A Phase 2 Trial of Belzupacap Sarotalocan, a Targeted Investigational Therapy for Choroidal Melanoma via Suprachoroidal Administration

Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD

Retrieved on: 
Mittwoch, November 1, 2023
Axitinib, CLS, AMD, Injection, Pharming, OASIS, Disease, Paratriathlon, Clinical trial, Clearside, Eye, Safety, Patient, Pharmaceutical industry

ALPHARETTA, Ga., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the completion of recruitment in its ODYSSEY Phase 2b clinical trial, a randomized, double-masked, parallel-group, active-controlled, multi-center study in participants with neovascular age-related macular degeneration (wet AMD). ODYSSEY is evaluating the safety and efficacy of CLS-AX (axitinib injectable suspension), a highly potent tyrosine kinase inhibitor delivered directly to the site of disease via Clearside’s SCS Microinjector®.

Key Points: 
  • ALPHARETTA, Ga., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the completion of recruitment in its ODYSSEY Phase 2b clinical trial, a randomized, double-masked, parallel-group, active-controlled, multi-center study in participants with neovascular age-related macular degeneration (wet AMD).
  • ODYSSEY is evaluating the safety and efficacy of CLS-AX (axitinib injectable suspension), a highly potent tyrosine kinase inhibitor delivered directly to the site of disease via Clearside’s SCS Microinjector®.
  • Following the completion of recruitment, final participants will be randomized to the CLS-AX treatment arm or the aflibercept comparator arm by the middle of December 2023.
  • “The efficacy and safety results from the study will guide the path forward for our pivotal Phase 3 development program for CLS-AX.